Keeping Track: J&J Amivantamab, Infectious Disease Agents From Iterum, VBI And Atox Submitted; Another Furoscix CRL
Executive Summary
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
You may also be interested in...
ScPharmaceuticals Hopes To Win Payer Favor As It Prepares For Furoscix Resubmission
The company announced interim results of the FREEDOM-HF study showing nearly $18,000 in savings per heart failure patient.
J&J’s Rybrevant May Find Limited Uptake Outside Academic Centers
The lung cancer drug’s side effects may deter some community oncologists, while a potentially safer drug earlier in development could prove more attractive.
Five New EU Filings Leave Starting Blocks at EMA
There is one orphan drug among the five new marketing authorization applications that the European Medicines Agency has under review. All five drugs will be reviewed under standard review timelines.